

Push to Boost Space

ngana with a 7% share each. The future of the EV industry is bright, and real estate will play a vital role in shaping its trajectory. As demand for EV manufacturing facilities, charging infrastructure, and associated services expands, the real estate sector will need to adapt and provide the necessary infrastructure and space to accommodate this growth," said Ram Chandnani, managing director, Advisory & Transactions Services, CBRE India. This year, the EV sector has recorded investment announcements of about \$6.2 billion to date. In 2022, investments of more than \$1 billion were announced in the EV industry, surging about 15% from \$4.4 billion in 2021. More than half the investments were made by EV component manufacturers, multiple e-mobility startups are concentrating their presence in the primary motive clusters in India. Uttar Pradesh took the lead in registered annual sales in 2022 with a 16%, followed by Maharashtra and Karnataka (9%). India's EV market is expected to grow at a compound annual growth rate of about 49% between 2020 and cross annual sales of 1 million units by 2030.

Stake in Control

20% paid up capital of the company to the Godrej Properties. In this, Madhuvan Enterprises, which is engaged in the business of construction and development of commercial premises, has become an associate entity of Godrej Properties with effect from May 30. Godrej Properties recorded a turnover worth Rs 4,051 crore for the quarter ended March, taking its performance to Rs 12,232 crore up 56% and more than fifth of the annual guidance. Sales volumes for the fourth quarter climbed 19% sequentially in terms of 5.25 million sq ft against 4.2 million sq ft. During the quarter, sales volumes rose 40% to 10.84 million sq ft from 10.84 million sq ft. This is the company's highest quarterly and annual sales volume. In addition to sales, the company's cash collections, project deliveries also touch high. Earlier exclusive interactive Chairman Piroj Shah had told ET that the company is positioned well to surmount the challenging guidance of Rs 12,000 crore for FY23.

TARC Banks on High Demand for Luxe Homes to Triple Revenue This Fiscal: CEO

Faizan.Haldar
@timesgroup.com

New Delhi: Delhi-based real estate developer TARC Limited is looking to triple its revenue in this financial year to ₹1,500 crore on the back of robust demand for luxury residential projects, said its CEO Amar Sarin.

He told ET that the company achieved project sales value of ₹520 crore in 2022-23 and has planned two launches in central Delhi and Gurgaon this year.

The company, which has raised ₹1,330 crore from Bain Capital by way of non-convertible debentures, is expecting revenue of Rs 6,000 crore from these projects.

"Both the projects we are planning to launch by September-October 2023. They will have a development potential of around 3 million sq ft. However, initially we will launch phase-1 and subsequently more phases will be launched," said Sarin.

This year, the company also expects revenue from the luxury residential project TARC Trigundra, on the main Bijwasan Road in Delhi, which it launched in 2022.



The premium project offers three-BHK and four-BHK homes priced ₹4.5 crore onwards and the project has an approximate total sales value of about Rs 900 crore, which is significantly higher than the earlier contemplated value of ₹650 crore due to price appreciation.

"Our other project in Gurgaon, TARC Maceo, is sold out and has achieved price escalation of 45%. In 2022-23 registered cash inflows of ₹250 crore, including compensation received from the government for land acquisition. Due to this, we were able to meet payment obligations ahead of the scheduled time," said Sarin.

TARC Ltd has also prepaid ₹67.96 crore towards NCDs. In December 2022 also, the company had prepaid ₹66.36 crore.

With the prepayment made in last financial year 2022-23, the company has fulfilled the payment obligation of ₹100 crore before the due date of June 30, 2023.

"This pre-payment enhances investor confidence in TARC as it showcase proactive debt management and financial stability. It also adds operational flexibility enabling us to pursue growth opportunities, adapt to changing market conditions, and generate cost savings through lower interest expenses, thereby positively impacting our financial performance," said Amar Sarin, MD & CEO of TARC Limited.

Govt Bans Drugs over Risks to

Move comes after recommendations by expert panel and drugs advisory board

Teena.Thacker
@timesgroup.com

New Delhi: The government on Friday banned 14 fixed-dose combination (FDC) drugs citing lack of therapeutic justification following recommendations by an expert panel.

A FDC contains two or more active ingredients in a fixed dose ratio.

According to the government notification, the expert committee recommended that "the no therapeutic justification for these FDC and they may be "at risk" to human beings.

"Hence, in the larger public interest, it is necessary to prohibit the manufacture, sale or distribution of this FDC under section 26A of the Drugs and Cosmetics Act, 1940," the notification said.

It stated that any kind of restriction or restriction to allow for use in patients is not "justifiable". "Therefore, only prohibition under Section 26A is recommended", it further said.

These FDCs are commonly used for treating cough, fever, infections, fever body ache. They include Nimesulide+ Paracetamol dispersible tablets, Amoxicillin+ Bromhexine, Pholcodine+ methazine, Chlorpheniramine maleate + Dextromethorphan, Guaiphenesin + Ammonium Chloride + Menthol, Chlorpheniramine Maleate + Codeine, Ammonium Chloride + Bromhexine + Dextromethorphan + Ammonium Chloride + Menthol, Dextromethorphan + Chlorpheniramine + Guaiphenesin + Ammonium Chloride + Bromhexine + Salbutamol + Guaiphenesin, Salbutamol + Bromhexine, Chlorpheniramine + Codeine Phosphate + Menthol, Syrup Phenytoin + Phentolamine sodium, Ammonium Chloride + Sodium Citrate + Chlorpheniramine Maleate + Bromhexine (100mg + 40mg + 2.5mg + 125mg + 55mg + 4mg + 110mg + 46mg + 3mg + 0.1mg), (130mg + 55mg + 3mg + 0.1mg) 5ml syrup, Salbutamol + yethylltheophylline (Etoposide and Bromhexine).

Earlier in 2016, the government had restricted about 54 varieties of FDCs after an expert panel declared them as